NORTH CHICAGO, Ill.,
Jan. 8, 2020 /PRNewswire/ -- AbbVie
(NYSE: ABBV), a research-based global biopharmaceutical company,
today announced the creation of a new global business, Allergan
Aesthetics, an AbbVie company, and the proposed leadership team for
the combined company, effective upon the expected first-quarter
2020 close of the Allergan acquisition.
Allergan Aesthetics will operate as a new global dedicated
business with its own research and development function under the
AbbVie umbrella and will include leading aesthetic products
including, BOTOX Cosmetic, the JUVEDERM collection of dermal
fillers and COOLSCULPTING body contouring, among others. This
global business, located in Irvine,
California, will be led by Carrie
Strom, currently Senior Vice President, U.S. Medical
Aesthetics, Allergan. Upon completion of the Allergan acquisition,
Ms. Strom will be named Senior Vice President, AbbVie and
President, Global Allergan Aesthetics. She will oversee the
worldwide operations, along with an experienced team of current
Allergan leaders, and report directly to Richard A. Gonzalez, Chairman and Chief
Executive Officer, AbbVie.
The Eye Care and Specialty businesses – including BOTOX
Therapeutics, Central Nervous System, Women's Health and
Gastrointestinal Diseases – will be integrated into the existing
AbbVie organization. Several Allergan leaders have accepted
leadership positions in the future company across these
franchises.
The following individuals will make up the Executive Leadership
team of the combined company:
- Richard A. Gonzalez, Chairman
and Chief Executive Officer
- Laura Schumacher, Vice Chairman,
External Affairs and Chief Legal Officer
- Michael E. Severino, M.D., Vice
Chairman and President (including Research and Development)
- Carlos Alban, Vice Chairman,
Chief Commercial Officer
- Henry O. Gosebruch, Executive
Vice President, Chief Strategy Officer
- Robert A. Michael, Executive
Vice President, Chief Financial Officer
- Timothy J. Richmond, Executive
Vice President, Chief Human Resources Officer
- Azita Saleki-Gerhardt, Ph.D.,
Executive Vice President, Operations
- Carrie Strom, Senior Vice
President, AbbVie, and President, Global Allergan Aesthetics
"We are enthusiastic about the potential of the new AbbVie and
continue to make significant progress on completing our acquisition
of Allergan," said Richard A.
Gonzalez, chairman and chief executive officer, AbbVie.
"Today's announcement marks an important step forward in our plans
to create the integrated global company. We are fortunate to
have a leadership team with a deep breadth of both industry and
company experience and we are excited to welcome the new Allergan
leaders to our Company."
About AbbVie
AbbVie is a global, research-driven
biopharmaceutical company committed to developing innovative
advanced therapies for some of the world's most complex and
critical conditions. The company's mission is to use its expertise,
dedicated people and unique approach to innovation to markedly
improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than
75 countries, AbbVie employees are working every day to advance
health solutions for people around the world. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
Twitter or view careers on our Facebook or LinkedIn page.
The Directors of AbbVie Inc. accept responsibility for the
information contained in this announcement. To the best of their
knowledge and belief (having taken all reasonable care to ensure
such is the case), the information contained in this announcement
is in accordance with the facts and does not omit anything likely
to affect the import of such information.
Any holder of 1% or more of any class of relevant securities
of AbbVie Inc. may have disclosure obligations under Rule 8.3 of
the Irish Takeover Panel Act, 1997, Takeover Rules 2013.
View original
content:http://www.prnewswire.com/news-releases/abbvie-announces-leadership-team-and-creation-of-new-business-allergan-aesthetics-upon-completion-of-acquisition-300983223.html
SOURCE AbbVie